A prototype of a novel diagnostic assay for cervical pre-cancer and cancer has been developed in both a sandwich ELISA-based and a lateral flow–based format (“strip test”). The test specifically detects presence of high-risk HPV-E6 and therefore promises to be of higher predictive value for cervical pre-cancer and cancer than other assays detecting merely presence of HPV. Presented at: 22rd International Papillomavirus Conference and Clinical Workshop, September 1, 2006; Vancouver, Canada.
Author(s): Schweizer J, Somoza C, Peck R, et al
Corporate author(s): PATH, Arbor Vita Corporation
Publication date: September 2006
113 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- Health technologies > Diagnostic technologies
- Reproductive health > Cervical cancer prevention
- Reproductive health > Sexually transmitted infections
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA